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Background: The etiology of inflammatory bowel disease (IBD) is not clear and cytomegalovirus (CMV) infection is
often associated with IBD patients. The etiologic link between IBD and CMV infection needs to be studied. The
objective of the present study is to investigate the prevalence and risk factors of CMV in a cohort of IBD patients
from Central China.
Methods: Two hundred and twenty six IBD patients (189 ulcerative colitis (UC) and 37 patients with Crohn’s
disease (CD)), and 290 age and sex matched healthy controls were recruited. CMV DNA was detected by nested
PCR, while serum anti-CMV IgG and anti-CMV IgM was determined by ELISAs. Colonoscopy/enteroscopy with
biopsy of diseased tissues and subsequent H&E stain were then conducted in IBD patients with positive anti-CMV
IgM. Finally, we analyzed the prevalence and clinical risk factors of CMV infection in IBD patients.
Results: The prevalence of CMV DNA and anti-CMV IgG positive rate in IBD patients were 84.07% and 76.11%,
respectively, higher than those in healthy controls (59.66% and 50.69%, respectively, P < 0.05), However, anti-CMV
IgM positive rate was no different with healthy controls (1.77% vs 0.34%, P = 0.235). In univariate analysis of risk
factors, the recent use of corticosteroid was associated with increase of CMV DNA and IgM positive rate in UC
(P = 0.035 and P = 0.015, respectively), aminosalicylic acid drug therapy was correlated with positivity of CMV DNA
and IgG in UC and CMV DNA in CD (P = 0.041, P < 0.001 and P = 0.014, respectively), the treatment of
immunosuppresent was correlated with CMV IgM (P < 0.001). Furthermore, patients with severe UC were
significantly associated with CMV DNA and IgM (P = 0.048 and P = 0.031, respectively). Malnutrition (albumin
< 35 G/L) was also found to be related with CMV recent infection (P = 0.031). In multivariate analysis of risk factors
in UC, pancolitis was significantly associated with CMV DNA positivity (P = 0.001). Severe UC and pancolitis seemed
to be related with IgG positivity. For CD, there was just single factor associated with CMV positive in each group,
multivariate analysis was unnecessary.
Conclusions: CMV positive rate in IBD patients was significantly higher, than in healthy controls. The use of
aminosalicylic acid, corticosteroid, immunosuppressants, pancolitis and severe IBD patients seemed to be more
susceptible to CMV infection in univariate analysis of risk factors. However, no risk factor was found to be
significantly correlated with CMV infection in multivariate analysis of risk factors.
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Inflammatory bowel disease (IBD) including ulcerative
colitis (UC) and Crohn’s disease (CD), consists of chronic,
non-specific inflammatory diseases of the gut with un-
known etiology. According to a retrospective survey, the
incidence and prevalence of IBD in China are on the rise
[1], and IBD is gradually become one of the refractory in-
testinal diseases. Even though the etiology of IBD is un-
known, recent studies have shown that the pathogenesis
of IBD is related to susceptible genes, immune dysregula-
tion and microbiota of the gut.
Cytomegalovirus (CMV) is a β herpes virus with
double-stranded DNA. Worldwide the current infective
rate ranges between 40% and 100% [2]. Two studies in
USA demonstrated that CMV positive rate in patients
with acute severe colitis was 21–34%, in corticosteroid-
refractory cases was 33–36%, and in active UC was 10%
[3,4]. In Egypt, the CMV positive rate was 34.8% in
corticosteroid-refractory IBD patients [2]. However, the
prevalence of CMV in Chinese patients with IBD has
not been reported in the literature till now.
CMV infection in IBD patients often makes clinical
diagnosis and treatment complex. Maher et al. [2] have
shown that IBD patients with CMV-positive were more
likely to get fever, cervical lymphadenopathy, splenomeg-
aly, leucopenia, thrombocytopenia, and pancolitis as
compared to CMV-negative ones. Kandiel et al. [3] used
antiviral drugs for the treatment of acute severe CMV-
positive colitis, and achieved a remission rate of 67–
100%. However, Lévêque et al. [5] found no relationship
between CMV viral load and disease severity in patients
with active IBD. Out of 7 CMV-positive patients treated
with immunosuppressants and no antiviral therapy, re-
mission was achieved in 5 patients. de Saussure et al. [6]
treated 3 CMV-positive IBD cases with antiviral therapy,
and only 1 patient got remission. Recently a study on
cytomegalovirus infection in IBD undergoing treatment
of anti-TNF-αantibody demonstrated that active CMV
infection did not progress to CMV infection/disease fol-
lowing infliximab therapy, the response to infliximab
therapy did not appear to be influenced by, or influence
the course of, CMV infection/disease [7]. These studies
aided in proving a link between CMV infection and re-
fractory IBD. However, due to the small cohorts in some
studies, further studies with larger cohorts need to be
conducted in order to find a conclusive relationship be-
tween CMV and IBD.
Nested PCR of CMV-UL93 is considered to be a
highly sensitive method for the detection of CMV [8].
Serum anti-CMV IgG and IgM are widely used in prac-
tice. The detection of IgG antibodies against CMV
should be detected at the first visit, when the diagnosis
of IBD is confirmed, in order to clarify whether the pa-
tient is at risk of displaying primary infection (IgGnegative) or reactivation/reinfection (IgG positive). How-
ever, IgM antibodies to CMV are systematically detected
in primary infection, reactivation or reinfection, it indi-
cates CMV infection is in active stage. With primary in-
fection, an early IgM antibody rise occurs and becomes
detectable in the blood within the first week of infection.
Anti-CMV IgM increases within 2 weeks of infection,
and can remain positive for 3 months to 2 years. Its sen-
sitivity and specificity for CMV infection could reach up
to 100% and 98.6% respectively [9].
In this study, PCR detection of CMV DNA, and sero-
logical determinations of IgG and IgM were used to in-
vestigate the prevalence of CMV infection in IBD
patients from central China. Moreover, risk factors for
CMV infection in IBD patients were analyzed to find re-
lationship between IBD and CMV infection.
Methods
Patients and healthy controls
From 2006 to 2011, 226 IBD patients (189 UC and 37
patients with CD) were recruited from Zhongnan Hos-
pital of Wuhan University School of Medicine. The diag-
nosis of UC and CD was based on clinical, laboratory,
imaging, endoscopic and histological examinations, and
in accordance to the Chinese Medical Association diag-
nostic criteria for IBD [10]. Clinical disease activity of
UC and CD was assessed by Truelove and Witts criteria
[11] and Crohn’s disease activity index (CDAI) respect-
ively [12].
Simultaneously, 290 sex and age matched healthy volun-
teers (controls) were recruited in Zhongnan Hospital
Medical Center of Wuhan University, who attended this
center for constitutional examination of health. All volun-
teers were unrelated to each other from Hubei province,
and had no history of IBD, chronic infectious diseases, im-
mune-mediated, ischemic and radiation-induced diseases.
Subjects with history of use of corticosteroids and im-
munosuppressive agents, of drug abuse and unhealthy liv-
ing were excluded from the study.
Definitions
The patients and controls were classified as current
smokers if they had smoked more than 1 cigarette per
day within 6 months before recruited, and nonsmokers
if they never or rarely smoked. As for definition of alco-
hol drinking before the onset of symptoms, 3 categories
were included: frequent drinking, light drinking and
former drinking. Frequent drinking was defined as alco-
hol drinking 3 days or more per week for continuous
6 months before recruited, excluded drink everyday to
alcoholic intoxication. Light drinking was defined as al-
cohol beverages less than 3 days per week. Former
drinking was defined as patients who had quit drinking
for more than 6 months before recruited. They were all
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or rarely drinking. Mixed food was defined as the com-
position of diet include vegetable and meat for at least
6 months before recruited. The severity of UC was
assessed by Truelove and Witts criteria [11]: Severe diar-
rhoea (six or more motions a day) with macroscopic
blood in stools. Fever (mean evening temperature more
than 37.5°C, or a temperature of 37.8°C, or more on at
least two days out of four). Tachycardia (mean pulse rate
more than 90 per minute). Anaemia (haemoglobin 75%
or less-allowance made for recent transfusion). ESR
much raised (more than 30 mm in one hour). Mild diar-
rhoea (four or less motions a day) with no more than
small amounts of macroscopic blood in stools. No fever.
No tachycardia. Anaemia not severe. ESR not raised
above 30 mm. in one hour. Moderately-Intermediate be-
tween severe and mild [11]. The severity of CD was clas-
sified by Best CDAI: Index values between 150 and 220
are associated with mild disease; values between 220 and
450 are moderate disease; and values above 450 are seen
with severe disease [12]. Drugs use was defined as taking
related drugs for a period of at least 2 months to the
time recruited.
Ethics statement
The ethic committee of Zhongnan Hospital of Wuhan
University approved the study. Consent was written by
all subjects. Consent informed in current ethics state-
ment was obtained from all participants involved in
this study.
Extraction of DNA
5 ml venous blood was taken in anticoagulated tubes
with ethylenediamine tetraacetic acid (EDTA) from all
subjects, followed by centrifugation. 2 ml of sera was
taken and stored at −80 degrees for further anti-CMV
IgG and IgM assay. Genomic DNA was extracted using
proteinase K and phenol/chloroform method, which was
then subsequently stored at −80 degrees.
CMV-UL93 fragment detection
The CMV-UL93 fragment was retrieved from NCBI and
BLAST, and was imported into Primer 5.0, according to
the primer design principle. Lateral primers consisted of
an upstream primer 50-GGCAGCTATCGTGACTG
GGA-30, and a downstream primer 50-GATCCGACC
CATTGTCTAAA-30. PCR conditions included 40 cycles
of 95°C for 10 min, 95°C for 30 s, 57°C for 30 s, 72°C
for 60 s, and then followed by 72°C for 10 min. Inner
primers were an upstream primer 50-TTAGCGCGT
GACCTGTTACG-30, and a downstream primer 50-
TCTAAATTGTTACGCAGTCCG-30. PCR conditions
included 40 cycles of 95°C for 10 min, 95°C for 30 s,
58°C for 30 s, 72°C for 60 s, and finally followed by 72°Cfor 10 min. Then electrophoresis using 2.5% agarose gel,
of the medial segment was done to identify the products
of PCR. Direct sequence for PCR products was done for
detection of positive and negative PCR products. DNA-
PCR+ was according to the result of electrophoresis of
nested PCR, and ensured the result by DNA sequencing.
Serum anti-CMV IgG and IgM detection
ELISA kit (DIESSE Diagnostica senese, Italy) was used
to detect serum anti-CMV IgG and IgM in IBD patients
and healthy controls. CMV IgG+ and CMV IgM+ were
according to the kit: Positive defined as optical density
(OD) ratio of sample to standard threshold value greater
than 1.1, negative below 0.9.
Histology and hematoxylin and eosin (H&E) staining
Colonoscopy and/or enteroscopy were conducted in
anti-CMV IgM-positive IBD patients, and biopsies from
pathological sites were taken. H&E staining for the de-
tection of CMV was done.
Statistical analysis
SPSS 13.0 software (SPSS for Windows version 13.0,
Chicago, IL, USA) was used to conduct the statistical
analysis. Measurement data are presented as mean ±
standard deviation (SD), and numeration data are
expressed as percentage and the number of cases. Inde-
pendent samples were analyzed by Levene’s test. χ2(Chi-
square) test with Yates continuity correction or Fisher’s
exact test was performed to compare frequencies of risk
factors between the IBD patients and healthy controls.
Multiple logistic regression analysis was performed to
evaluate multiple risk factors for IBD. Odds ratio (OR)
and 95% confidence intervals (CI) were calculated. All
calculated P-values were 2-sided and P < 0.05 was con-
sidered significant.
Results
Demographic and clinical profile
As shown in Table 1, Patients with inflammatory bowel
disease and heathy controls were age- and sex-matched
(P > 0.05), demographic and clinical profile were included
in this table.
CMV-UL93 fragment, and CMV IgG, IgM detection
As shown in Table 2, prevalence of CMV-UL93 and
anti-CMV IgG were significantly higher in IBD patients,
than in healthy controls (84.07% vs 59.66%, P < 0.001;
76.11% vs 50.69%, P < 0.001), However, prevalence of
anti-CMV IgM was no different with healthy controls
(1.77% vs 0.34%, P = 0.235). For UC patients, CMV-
UL93 and anti-CMV IgG were all significantly higher
than in healthy controls (P < 0.001 and P < 0.001, re-
spectively), While there was no difference between UC
Table 1 Demographic and clinical profile of the inflammatory bowel disease patients and healthy controls
UC CD IBD Healthy controls P value
n = 189(%) n = 37(%) n = 226(%) n = 290(%)
Mean age ± SD (yr) 40.81 ± 15.00 38.78 ± 14.14 40.66 ± 14.90 38.08 ± 14.63 0.888
Male/Female 109/80 23/14 132/94 170/120 0.961
Smoking 45 (23.81%) 9 (24.32%) 54 (23.89%) 101 (34.83%) 0.007*
Drinking 75 (39.68%) 12 (32.43%) 87 (38.50%) 133 (45.86%) 0.093
Diet composition
vegetarian food 18 (9.52%) 6 (16.22%) 24 (10.62%) 19 (6.55%) 0.097
mixed food 171 (90.48%) 31 (83.78%) 202 (89.38%) 271 (93.45%)
General state
fever 32 (16.93%) 4 (10.81%) 36 (15.93%)
hemoglobin (g/L) 114.10 ± 23.98 121.22 ± 25.34 115.71 ± 24.37
albumin (g/L) 39.97 ± 5.88 38.12 ± 6.44 39.94 ± 6.04
Disease extent







severe 21 (11.1%) 7 (18.92%)
Treatment
ASA/SASP 149 (78.84%) 20 (54.05%) 169 (74.78%)
corticosteroids 47 (24.87%) 8 (21.62%) 55 (24.34%)
immunodepressant 5 (2.65%) 2 (5.41%) 7 (3.10%)
CMV, cytomegalovirus; UC, ulcerative colitis; CD, Crohn’s disease; ASA, aminosalicylic acid; SASP, salicylazosulfapyridine.
*indicate significant difference.
Table 2 Prevalence of cytomegalovirus (CMV) in patients with inflammatory bowel disease and healthy controls
IBD UC CD Healthy controls
(n = 226) (n = 189) (n = 37) (n = 290)
CMV detection n (%) n (%) n (%) n (%)
DNA DNA+ 90 (84.07)a 161 (85.19)d 29 (78.38)g 173 (59.66)
Serum CMV IgG+ 172 (76.11)b 139 (73.54)e 33 (89.19)h 147 (50.69)
Serum CMV IgM+ 4 (1.77)c 3 (1.59)f 1 (2.70)i 1 (0.34)
a Compare with healthy controls, OR = 3.569, 95% CI: 2.330-5.468, P < 0.001;
b Compare with healthy controls, OR = 3.099, 95% CI: 2.113-4.543, P < 0.001;
c Compare with healthy controls, OR = 5.207, 95% CI: 0.578-46.914, P = 0.235;
d Compare with healthy controls, OR = 3.889, 95% CI:2.443-6.190, P < 0.001;
e Compare with healthy controls, OR = 2.704, 95% CI:1.819-4.022, P < 0.001;
f Compare with healthy controls, OR = 4.661, 95% CI:0.481-45.148, P = 0.344;
g Compare with healthy controls, OR = 2.452, 95% CI:1.083-5.550, P = 0.027;
h Compare with healthy controls, OR = 8.026, 95% CI:2.772-23.232, P < 0.001;
i Compare with healthy controls, OR = 8.028, 95% CI:0.491-131.142, P = 0.540.
IBD, inflammatory bowel disease; CMV, cytomegalovirus; UC, ulcerative colitis; CD, Crohn’s disease.
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CD patients, CMV-UL93 and anti-CMV IgG were higher
than in controls (P = 0.027 and P < 0.001, respectively),
while anti-CMV IgM was not increased as compared to
healthy controls (P = 0.540).
However, in biopsies taken from the pathological sites of
intestinal mucosa of anti-CMV IgM positive IBD patients,
no inclusion bodies were detected in H&E stain.
Univariate Analysis of Risk factors for CMV positive in
patients with IBD
In UC patients, elevated CMV-DNA was mainly asso-
ciated with the severity of disease activity (P = 0.048),
use of ASA/SASP (aminosalicylic acid/salicylazosulfapyr-
idine) and corticosteroids therapy (P = 0.041 and P =
0.035, respectively), while other factors, such as age,
sex, smoking, alcohol consumption, type of diet, fever,
anemia, albumin level, disease location, treatment with
immunosuppressive agents had not shown significant
association (P > 0.05). As for CD patients, CMV DNA
positive was positively associated with use of 5-ASA/
SASP (P = 0.014), as seen in Table 3.
In UC patients, anti-CMV IgG level was associated
with the use of 5-aminosalicylic acid (P < 0.001) as
shown in Table 4. CD patients on vegetarian diet had
much lower anti-CMV IgG positive rate, than those on
non-vegeterian diet (P = 0.010). Other factors had no sta-
tistically significant impact on anti-CMV IgG positive
rate (P > 0.05).
The positive rate of anti-CMV IgM in UC patients,
was associated with low albumin level (P = 0.031), severe
UC (P = 0.031), use of corticosteroids (P = 0.015), and
the use of immunosuppressive agents (P < 0.001), while
other factors did not cause any statistically significant
changes in anti-CMV IgM positive rate (P > 0.05). In CD
patients, no statistically significant association with anti-
CMV IgM was found, as shown in Table 5.
Multivariate analysis by logistic regression for CMV
positive in IBD
As shown in Table 6. In multivariate analysis of risk fac-
tors in UC, pancolitis was significantly associated with
CMV DNA elevated (P = 0.001). Severe UC and pancoli-
tis seemed to be related with IgG positive (P = 0.021 and
P = 0.017, respectively). For CD, there was just single fac-
tor associated with CMV positive in each group, multi-
variate analysis was unnecessary.
Discussion
CMV is an opportunistic pathogenic microorganism. In
vivo it can proliferate in epitheliums, white blood cells
and sperm cells, and it is prone to cause latent infection
of salivary gland, mammary gland, kidney and white
blood cells. In IBD patients, immunosuppressive therapy,impaired absorption of nutrients, dysfunction of the im-
mune system, render them susceptible to CMV infection
[13], which is consistent with the high infective rate of
CMV in immunosuppressed individuals, such as acquired
immunodeficiency syndrome (AIDS), transplant recipi-
ents, cancer, chemotherapy, but rare in immunocompe-
tent individuals.
The detection methods of CMV infection in IBD
patients included DNA detection, serological tests
(serum anti-CMV IgM, IgG), histopathology (inclusion
bodies detection) in this study. Body fluids or tissue
sample was feasible to CMV culture, but it was time-
consuming and also had low sensitivity, which limited
clinical application [14]. The detection of CMV-DNA
was considered as the most sensitive method [15], but it
was associated with false positive results, thereby de-
creasing its specificity. Increase in serum anti-CMV IgM
level occurred in recent CMV infection and it had high
sensitivity and specificity [9], while anti-CMV IgG indi-
cated past CMV infection. Sensitivity of H&E was 10%
to 87% [3], CMV inclusion bodies could be found in bi-
opsy specimens from colon with inflamed and ulcerated
mucosa [16]. We used CMV-DNA specific fragment
UL93, anti-CMV IgG and IgM to detect CMV infection
in IBD patients and healthy controls. Positive rates in
IBD patients were 84.07%, 76.11%, 1.77% for CMV
DNA, anti-CMV IgG and IgM respectively, and 59.66%,
50.69%, 0.34% for healthy controls. CMV-UL93 and
anti-CMV IgG were significantly higher in IBD patients
as compared to controls, thereby indicating the associ-
ation between IBD and CMV.
The positive rate of CMV UL-93 or anti-CMV IgG in
the healthy controls was about 50–60%, whereas in IBD
patients it was around 70–80%. A research conducted in
India showed the CMV DNA positive rate was just
12.70% in IBD patients [17], which was remarkably
lower than in our country. The small number of subjects
enrolled (63 IBD patients) could account for the low
positive rate in the Indian study. Another research done
in France showed 60% positive rate in IBD patients [18],
which was consistent with our research. In developed
countries, the anti-CMV IgG positive rate was found to
be above 70% [19].
Anti-CMV IgM positive rate is only 1.77% in our re-
search, which was lower as compared to an Indian study,
including IBD patients with both active disease and in
remission [17], where the rate was 9.52%. Anti-CMV
IgM positive rate in healthy controls (0.34%) was no dif-
ferent with IBD patients (P = 0.235), which was related
with small amount of people included.
Presence of anti-CMV IgM indicated recent infection
of CMV. However in biopsies taken from the patho-
logical sites of intestinal mucosa of anti-CMV IgM posi-
tive IBD patients, no inclusion bodies was detected. This




Age Number P value OR (95% CI) Number P value OR (95% CI)
≤50 ys 117/22 0.514 0.725 (0.276 ~ 1.907) 18/6 0.685 0.545 (0.093 ~ 3.194)
>50 ys 44/6 11/2
Sex
male 95/14 0.373 1.439 (0.644 ~ 3.218) 19/4 0.445 1.900 (0.390 ~ 9.256)
female 66/14 10/4
Smoking
yes 40/5 0.423 1.521 (0.542 ~ 4.264) 7/2 1.000 0.840 (0.138 ~ 5.115)
no 121/23 25/6
Drinking
Yes 62/13 0.429 0.723 (0.322 ~ 1.621) 9/3 0.403 0.500 (0.100 ~ 2.510)
no 99/15 30/5
Diet composition
vegetarian food 15/3 1.000 0.856 (0.231 ~ 3.174) 3/3 0.101 0.192 (0.030 ~ 1.241)
mixed food 146/25 26/5
Fever
yes 30/2 0.221 2.977(0.670 ~ 13.235) 4/0 0.557 N/A
no 131/26 25/8
Hemoglobin(G/L)
≤70 8/1 1.000 1.412 (0.170 ~ 11.747) 0/0 - N/A
>70 153/27 29/8
Albumin(G/L)
≤35 18/3 1.000 1.049 (0.288 ~ 3.826) 11/2 0.685 1.833 (0.313 ~ 10.735)
>35 143/25 18/6
Disease severity
mild and moderate 140/28 0.048* N/A 24/6 0.631 1.600 (0.247 ~ 10.360)
severe 21/0 5/2
Location
distal colitis 123/17 0.080 2.094 (0.903 ~ 4.857)
pancolitis 38/11




ASA/SASP 131/18 0.041* 2.426 (1.017 ~ 5.784) 19/1 0.014* 13.300 (1.429 ~ 123.790)
corticosteroids 45/2 0.035* 5.043 (1.149 ~ 22.128) 8/0 0.160 N/A
immunosuppressant 5/0 1.000 N/A 2/0 1.000 N/A
CMV, cytomegalovirus; UC, ulcerative colitis; ASA, aminosalicylic acid; SASP, salicylazosulfapyridine.
*indicate significant difference.
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Age Number P value OR (95% CI) Number P value OR (95% CI)
≤50 ys 107/32 0.074 1.881 (0.934 ~ 3.786) 21/3 1.000 0.583 (0.054 ~ 6.251)
>50 ys 32/18 12/1
Sex
male 82/27 0.540 1.225 (0.639 ~ 2.349) 21/2 0.625 1.750 (0.218 ~ 14.069)
female 57/23 12/2
Smoking
yes 32/13 0.672 0.851 (0.404 ~ 1.793) 9/0 0.554 N/A
no 107/37 24/4
Drinking
Yes 53/22 0.467 0.784 (0.407 ~ 1.510) 10/2 0.582 0.435 (0.053 ~ 3.536)
no 86/28 23/2
Diet composition
vegetarian food 14/4 0.883 1.288 (0.403 ~ 4.115) 3/3 0.010* 0.033 (0.003 ~ 0.429)
mixed food 125/46 30/1
Fever
yes 26/6 0.278 1.687 (0.650 ~ 4.379) 4/0 1.000 N/A
no 113/44 29/4
Hemoglobin (G/L)
≤70 7/2 1.000 1.273 (0.255 ~ 6.341) 0/0 - N/A
>70 132/48 33/4
Albumin (G/L)
≤35 16/5 0.771 1.171 (0.405 ~ 3.381) 11/2 0.602 0.500 (0.062 ~ 4.040)
>35 123/45 22/2
Disease severity
mild and moderate 120/48 0.109 0.263 (0.059 ~ 1.173) 26/4 0.570 N/A
severe 19/2 7/0
Location
distal colitis 108/32 0.058 1.960 (0.971 ~ 3.955)
pancolitis 31/18




ASA/SASP 119/30 <0.001* 3.967 (1.897 ~ 8.296) 18/2 1.000 1.200 (0.150 ~ 9.570)
corticosteroids 38/9 0.190 1.714 (0.761 ~ 3.861) 8/0 0.557 N/A
immunosuppressant 5/0 0.328 N/A 2/0 1.000 N/A
CMV, cytomegalovirus; UC, ulcerative colitis; ASA, aminosalicylic acid; SASP, salicylazosulfapyridine.
*indicate significant difference.
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Age Number P value OR (95% CI) Number P value OR (95% CI)
≤50 ys 2/137 1.000 0.715 (0.063 ~ 8.065) 1/23 1.000 N/A
>50 ys 1/49 0/13
Sex
male 2/107 1.000 1.477 (0.132 ~ 16.573) 1/22 1.000 N/A
female 1/79 0/14
Smoking
yes 1/44 1.000 1.614 (0.143 ~ 18.222) 1/8 0.243 N/A
no 2/142 0/28
Drinking
yes 1/74 1.000 0.757 (0.067 ~ 8.496) 0/12 1.000 N/A
no 2/112 1/24
Diet composition
vegetarian food 0/18 1.000 N/A 0/6 1.000 N/A
mixed food 3/168 1/30
Fever
yes 1/31 1.000 2.500 (0.220 ~ 28.432) 0/4 1.000 N/A
no 2/155 1/32
Hemoglobin (G/L)
≤70 1/8 0.329 11.125 (0.911 ~ 135.909) 0/0 - N/A
>70 2/178 1/36
Albumin (G/L)
≤35 2/19 0.031* 17.579 (1.522 ~ 203.083) 1/12 0.351 N/A
>35 1/167 0/24
Disease severity
mild and moderate 1/167 0.031* 0.057 (0.005 ~ 0.657) 1/29 1.000 N/A
severe 2/19 0/7
Location
distal colitis 1/139 0.337 0.169 (0.015 ~ 1.907)
pancolitis 2/47




ASA/SASP 3/146 1.000 N/A 1/19 1.000 N/A
corticosteroids 3/44 0.015* N/A 0/8 1.000 N/A
immunosuppressant 3/2 <0.001* N/A 0/2 1.000 N/A
CMV, cytomegalovirus; UC, ulcerative colitis; CD, Crohn’s disease; OR, Odds ratio; CI, confidence interval; ASA, aminosalicylic acid; SASP, salicylazosulfapyridine.
*indicate significant difference.
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Table 6 Multivariate analysis by logistic regression for
CMV positive in ulcerative colitis
Index OR (95% CI) P
CMV DNA
Location 0.227 (0.093 ~ 0.553) 0.001*
Disease severity 0.000 (0.000~) 0.998
Fever 1.704 (0.357 ~ 8.138) 0.504
Treatment of corticosteroids 0.574 (0.228 ~ 1.449) 0.240
Treatment of ASA/SASP 1.761 (0.661 ~ 4.691) 0.258
CMV IgG
Age 0.893 (0.398 ~ 2.005) 0.784
Location 2.482 (1.145 ~ 5.380) 0.021*
Disease severity 0.078 (0.009 ~ 0.635) 0.017*
Treatment of ASA/SASP 0.749 (0.342 ~ 1.639) 0.470
CMV IgM
Alb 0.000 (0.000~) 0.997
Disease severity 0.840 (0.000~) 1.000
Treatment of corticosteroids 1.038 (0.000~) 1.000
Treatment of immunodepressant 0.997 (0.000~) 0.997
CMV, cytomegalovirus; OR, Odds ratio; CI, confidence interval; Alb, albumin;
ASA, aminosalicylic acid; SASP, salicylazosulfapyridine.
*indicate significant difference.
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examination. The site from where the biopsy was taken,
and the amount of tissue retrieved, may also influence
the sensitivity of finding inclusion bodies. Next stage we
should recruit enough biopsies and screen CMV by
immunohistochemistry.
In a model of multivariate analysis adjusting for mul-
tiple factors for UC. Disease location seemed to be sig-
nificantly associate with CMV infection or re-activation,
this may be associated with the theory that CMV was
prone to proliferate in granulation tissue [20]. Pancolitis
involved with larger areas of ulcerative mucosa, which
promote proliferation of CMV. Some researches [21]
found that CMV was readily discovered in granulation
tissue and tissue from deep ulcers, which suggested that
CMV could penetrate inflamed mucosa via mononuclear
cells, and then proliferate in the mucosa. A recent study
[22] showed that the murine CMV (MCMV) could not
induce acute colitis, but the latent MCMV infection
could increase the severity of the dextran sulfate sodium
(DSS) induced colitis. Moreover, acute MCMV infection
could significantly increase the serum and intestinal nat-
ural killer cells, interleukin (IL)-6, TNF-α, IFN-γ, indicat-
ing that CMV infection can modulate mucosal
immunity, thereby increasing susceptibility to inflam-
mation. CMV infection can also activate oncogenes,
kinases, transcription factors inducing tumorigenesis,which may be one of the reasons of the higher inci-
dence of colorectal cancer in IBD patients [23]. CMV
played a role in the initiation and progression of in-
flammation in IBD. The treatment of 5-ASAs, corticos-
teroids and immunosupressents were no longer
significant associated with CMV infection in multivari-
ate analysis.
Currently there is no absolute indication for antiviral
therapy in CMV-positive IBD patients. However Eddleston
recommends antiviral therapy in immunocompetent
[24]. Pfau [21] found out that ganciclovir could reduce
mortality rate and surgical intervention rate, while de
Saussure P [6] showed that antiviral therapy had no
effect on the disease course.
In summary, as compared to healthy individuals, IBD
patients have a predisposition to CMV infection. No risk
factor was found to be significantly correlated with
CMV infection in risk factors analysis.
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